Drugs / Plixorafenib
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06610682 | Apr 2025 → Jun 2027 expected | — | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06385119 | Apr → Dec 2024 | — | Fore Biotherapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02012231 | Feb → Sep 2014 | cholangiocarcinoma, colorectal cancer, hairy cell leukemia, histiocytosis +3 | Fore Biotherapeutics | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02428712 | Apr 2015 → Jul 2024 | — | Fore Biotherapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05503797 | Feb 2023 → Jun 2026 overdue | high grade malignant neoplasm | Fore Biotherapeutics | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | plixorafenib | “The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or...” NCT05503797 ↗ |
| Known as | FORE8394 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02428712 ↗ |
| Known as | PLX8394 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02012231 ↗ |
| Action | Inhibit | “selective inhibitor of BRAF” NCT02012231 ↗ |
| Modality | Small molecule | “PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.” NCT02012231 ↗ |
| Route | Oral | “orally available” NCT02012231 ↗ |
| Target | BRAF | “selective inhibitor of BRAF” NCT02012231 ↗ |